[Elimination half-life and serum protein binding of the anti-rheumatism agent naproxen in kidney failure].
Serum protein binding of naproxen is considerably reduced in patients with renal insufficiency. The hypothetical plasma concentration at time zero and the half life are not significantly altered in uremic patients in comparison with healthy subjects when the drug is given orally. This suggests an increased pharmacodynamic action in uremic patients when the drug is given in the usual dosage, since the pharmacologically active unbound part must then be increased.
D001798:Blood Proteins / Q000378:metabolism; D006207:Half-Life; D006801:Humans; D007676:Kidney Failure, Chronic / Q000378:metabolism*; D009288:Naproxen / Q000378:metabolism*; D011485:Protein Binding
D001798:Blood Proteins; D009288:Naproxen
Eliminationshalbwertszeiten und Serumproteinbindung des Antirheumatikums Naproxen bei Niereninsuffizienz.